Also known as: LY3502970
Orforglipron is an oral non-peptide GLP-1 receptor agonist marketed as Foundayo for chronic weight management in adults with obesity or overweight plus comorbidities. It is administered once daily and was evaluated in the ATTAIN trial program. The FDA first approved it on April 1, 2026.
Orforglipron beat oral semaglutide on blood sugar and weight in type 2 diabetes, with higher discontinuation rates. GLP-1 hair loss is typically temporary telogen effluvium.
Eli Lilly builds $1.5B stockpile for oral obesity drug orforglipron; study shows GLP-1s cut cancer risk; logistics firms invest in cold chain; and amylin drug race heats up with $19B in deals.
The FDA moved to exclude semaglutide, tirzepatide and liraglutide from its 503B compounding list. Eli Lilly won U.S. approval for its oral pill Foundayo, and Novo Nordisk sued Lilly over allegedly misleading weight-loss ads.
Can-Fite will present late-stage pipeline at BIO 2026; GlobalData counts over 2,000 peptides in development with $91.38bn 2025 sales; Arrowhead's RNAi pipeline has two Phase 3 programs.
Amgen shares have fallen 12.6% in three months despite relatively solid Q1 results, while Novo Nordisk maintains a 54.6% global GLP-1 market share. Both companies face pipeline competition and pricing pressures.
Global oncology drug spending is projected to reach $467 billion by 2030, driven by novel modalities like ADCs and bispecifics, but growth will slow due to patent expirations for key drugs like Keytruda and Lynparza. R&D is shifting, with novel modalities accounting for 33% of clinical trials in 2025. The industry is also seeing broader innovation and investment, with new blockbuster contenders emerging across multiple therapeutic areas.
Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.
GLP-1 drugs are still being studied for Alzheimer’s and addiction after semaglutide failed to slow cognitive decline in Alzheimer’s. A 2025 abstract reported semaglutide slowed cognitive impairment in an Alzheimer’s model.
The FDA has announced plans to crack down on active pharmaceutical ingredients used in compounded GLP-1 drugs and warned about the risks of these products. The agency has cited counterfeit products, non-FDA-approved ingredients and more than 1,000 adverse event reports tied to compounded semaglutide and tirzepatide.
Doctors said Americans starting obesity treatment are showing interest in oral GLP-1 drugs because of lower cost and convenience. Novo’s oral Wegovy and Lilly’s Foundayo are priced below injectable options.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07739537 |
PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses |
NOT_YET_RECRUITING | PHASE4 |
| NCT07729332 |
Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation |
NOT_YET_RECRUITING | PHASE4 |
| NCT07668336 |
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes |
NOT_YET_RECRUITING | PHASE3 |
| NCT07613307 |
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting |
RECRUITING | PHASE3 |
| NCT07241390 |
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) |
RECRUITING | PHASE3 |
| NCT07223593 |
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease |
RECRUITING | PHASE3 |
| NCT07202884 |
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight |
RECRUITING | PHASE3 |
| NCT07153471 |
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee |
RECRUITING | PHASE3 |
| NCT06993792 |
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06972472 |
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes |
ACTIVE_NOT_RECRUITING | PHASE3 |
